Regulatory FDA approves new high dose Spinraza regimen for SMA PharmaTimesUpdated dosing offers meaningful clinical benefitRegulatoryRare DiseaseRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) PharmaTimes Updated dosing offers meaningful clinical benefit RegulatoryRare DiseaseRead full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Viridian reports positive results from elegrobart phase 3 trialNext: Ambrosia adds a megaround for obesity drugs Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
